HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Telix Pharmaceuticals (NASDAQ: TLX) and maintained a price target of $20 for the stock. This endorsement suggests confidence in the company's future performance.